Ruxolitinib resistance or intolerance in steroid‐refractory acute graft‐versus‐host disease — a real‐world outcomes analysis. (12th July 2021)

• Record Type: Journal Article
• Authors: Abedin, Sameem; Rashid, Nahid; Schroeder, Mark; Romee, Rizwan; Nauffal, Mary; Alhaj Moustafa, Muhamad; Kharfan‐Dabaja, Mohamed A.; Palmer, Jeanne; Hogan, William; Hefazi, Mehrdad; Larson, Samantha; Holtan, Shernan; DeFilipp, Zachariah; Jayani, Reena; Dholaria, Bhagirathbhai; Pidala, Joseph; Khimani, Farhad; Grunwald, Michael R.; Butler, Candace; Hamadani, Mehdi
• Is Part Of: British journal of haematology. Volume 195:Number 3(2021)
• Page Start: 429
• Page End: 432
• Publication Date: 2021-07-12
• Subjects: graft‐versus‐host disease -- transplant -- stem cell transplantation; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.17700
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Ruxolitinib for steroid‐refractory acute graft‐ versus ‐host disease (SR‐aGVHD) results in resistance or intolerance in 1/5 of patients. Outcomes of such patients are undefined. We identified these patients in a multicentre review and reported outcomes. Ruxolitinib‐resistant aGVHD was identified in 48/307 patients. Among patients receiving additional therapy, the overall response rate to next therapy was 36%. Median survival was 21 days. Ruxolitinib intolerance led to treatment discontinuation in 16/307 patients. Ten intolerant patients received additional therapy with 50% experiencing continued improvement of aGVHD. Median survival was 50 days in these patients. These data serve as a baseline for future SR‐aGVHD studies.